Angel Pharmaceuticals
Jiaxing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing first-in-class and best-in-class oncology/autoimmune drugs through global partnerships and internal R&D.
OncologyImmunology
Technology Platform
Focuses on immunomodulation through targeting key nodes in T-cell signaling (ITK, BTK) and the adenosine pathway (CD73, A2A receptor) to enhance anti-tumor immune responses.
Opportunities
Potential first-in-class approval with CPI-818 in PTCL and expansion into autoimmune indications; differentiated CNS-penetrant BTK inhibitor (ANG-0623) for CNS lymphomas and MS; strategic China development rights for Corvus assets.
Risk Factors
Clinical development risks for novel mechanisms (ITK inhibition); funding requirements for multiple mid-to-late-stage trials; competitive intensity in BTK and adenosine pathway targeting.
Competitive Landscape
CPI-818 faces no direct clinical-stage competitors in ITK inhibition; ANG-0623 competes with other CNS-penetrant BTK inhibitors (e.g., tolebrutinib) in MS; adenosine pathway programs compete with multiple anti-CD73/A2A candidates from larger pharma.